Format

Send to

Choose Destination
Vaccine. 2003 Jan 30;21(7-8):678-83.

Experience with registered mucosal vaccines.

Author information

1
Berna Biotech Ltd, Rehhagstr 79, CH-3018, Berne, Switzerland.

Abstract

Most pathogens gain access to their host through mucosal surfaces. It is therefore desirable to develop vaccination strategies that lead to mucosal immune responses. Ideally, a vaccine should be administered mucosally in order to elicit mucosal protection. Several attenuated live viral and bacterial pathogens are registered as oral vaccines for human use, including the oral polio vaccine (Sabin) as well as attenuated strains of Salmonella typhi and Vibrio cholerae. These attenuated bacterial live vaccines-S. typhi Ty21a as well as V. cholerae CVD 103-HgR-are employed as vaccines against typhoid and cholera, respectively. In this manuscript, we review the immune responses that are induced by these vaccines, with a focus on mucosal immunity.

PMID:
12531339
DOI:
10.1016/s0264-410x(02)00579-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center